文献速递消化、代谢与肾脏急症

雷莫芦单抗联合多西他赛对比安慰剂联合多西他赛治疗铂类治疗后局部晚期或转移性尿路上皮癌(RANGE):随机双盲3期试验

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
PubMed 文献 · Lancet · 2017-09-12
一句话结论在铂类难治性晚期尿路上皮癌中,雷莫芦单抗联合多西他赛较安慰剂联合多西他赛显著延长无进展生存期(中位4.07 vs 2.76个月,HR 0.757)。

RANGE是一项在23个国家124个中心进行的随机双盲3期试验,纳入铂类化疗期间或之后进展的晚期或转移性尿路上皮癌患者,允许既往接受过一种免疫检查点抑制剂。患者1:1随机接受静脉多西他赛75 mg/m2联合静脉雷莫芦单抗10 mg/kg或匹配安慰剂,每21天重复,第1天给药,直至疾病进展或其他停药标准。主要终点为意向治疗分析的前437例随机患者的 investigator-assessed 无进展生存期。结果显示雷莫芦单抗组中位PFS显著延长(4.07 vs 2.76个月,HR 0.757,95%CI 0.607-0.943,p=0.0118),客观缓解率24.5% vs 14.0%。两组≥3级不良事件发生率相似(60% vs 62%),但雷莫芦单抗组脓毒症致死事件更常见(4例[2%] vs 0例[0%]),并报告1例中性粒细胞减少性脓毒症致死事件。

要点

  • 雷莫芦单抗联合多西他赛较安慰剂联合多西他赛显著延长中位PFS(4.07 vs 2.76个月,HR 0.757,95%CI 0.607-0.943,p=0.0118)。
  • 客观缓解率雷莫芦单抗组24.5%(53/216)vs 安慰剂组14.0%(31/221)。
  • 两组≥3级不良事件发生率相似(雷莫芦单抗组156/258[60%] vs 安慰剂组163/265[62%]),常见任何级别不良事件为乏力、脱发、腹泻、食欲下降、恶心,多为1-2级。
  • 雷莫芦单抗组治疗相关严重不良事件63/258(24%)vs 安慰剂组54/265(20%);治疗中或停药30天内死亡38/258(15%)vs 43/265(16%),研究者判定治疗相关死亡8/258(3%)vs 5/265(2%)。
  • 脓毒症是导致治疗中死亡的最常见不良事件(雷莫芦单抗组4例[2%] vs 安慰剂组0例[0%]),雷莫芦单抗组报告1例中性粒细胞减少性脓毒症致死事件。

适用人群与场景

  • 铂类化疗期间或之后进展的晚期或转移性尿路上皮癌患者。
  • 允许既往接受过一种免疫检查点抑制剂。

处置流程与药物剂量

  • 静脉多西他赛75 mg/m2联合静脉雷莫芦单抗10 mg/kg或匹配安慰剂,每21天重复周期的第1天给药,直至疾病进展或其他停药标准。

研究设计与关键结果

  • 随机双盲3期试验,纳入23个国家124个中心的530例患者,随机分配至雷莫芦单抗联合多西他赛组(n=263)或安慰剂联合多西他赛组(n=267)。
  • 主要终点为前437例随机患者的 investigator-assessed 无进展生存期,雷莫芦单抗组中位4.07个月(95%CI 2.96-4.47)vs 安慰剂组2.76个月(95%CI 2.60-2.96),HR 0.757(95%CI 0.607-0.943),p=0.0118;盲法独立中心分析结果一致。
  • 客观缓解率:雷莫芦单抗组53/216(24.5%,95%CI 18.8-30.3)vs 安慰剂组31/221(14.0%,95%CI 9.4-18.6)。
  • 最常见任何级别治疗中出现的不良事件(不论因果关系)为乏力、脱发、腹泻、食欲下降、恶心,多为1-2级。
  • ≥3级不良事件发生率:雷莫芦单抗组156/258(60%)vs 安慰剂组163/265(62%)。
  • 治疗相关严重不良事件:雷莫芦单抗组63/258(24%)vs 安慰剂组54/265(20%)。
  • 治疗中或停药30天内死亡:雷莫芦单抗组38/258(15%)vs 安慰剂组43/265(16%);研究者判定治疗相关死亡:雷莫芦单抗组8/258(3%)vs 安慰剂组5/265(2%)。
  • 导致治疗中死亡的最常见不良事件为脓毒症:雷莫芦单抗组4/258(2%)vs 安慰剂组0/265(0%);雷莫芦单抗组报告1例中性粒细胞减少性脓毒症致死事件。

证据类型、等级与局限

  • 证据类型:随机双盲3期试验。

对床旁实践的改变

  • 作者认为,雷莫芦单抗联合多西他赛是首个在3期研究中显示对铂类难治性晚期尿路上皮癌患者较化疗延长无进展生存期的方案。
  • 作者认为,这些数据验证了抑制VEGFR-2信号通路是尿路上皮癌的潜在新治疗选择。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed the efficacy and safety of treatment with docetaxel plus either ramucirumab-a human IgG1 VEGFR-2 antagonist-or placebo in this patient population.

METHODS: We did a randomised, double-blind, phase 3 trial in patients with advanced or metastatic urothelial carcinoma who progressed during or after platinum-based chemotherapy. Patients were enrolled from 124 sites in 23 countries. Previous treatment with one immune-checkpoint inhibitor was permitted. Patients were randomised (1:1) using an interactive web response system to receive intravenous docetaxel 75 mg/m2 plus either intravenous ramucirumab 10 mg/kg or matching placebo on day 1 of repeating 21-day cycles, until disease progression or other discontinuation criteria were met. The primary endpoint was investigator-assessed progression-free survival, analysed by intention-to-treat in the first 437 randomised patients. This study is registered with ClinicalTrials.gov, number NCT02426125.

FINDINGS: Between July, 2015, and April, 2017, 530 patients were randomly allocated either ramucirumab plus docetaxel (n=263) or placebo plus docetaxel (n=267). Progression-free survival was prolonged significantly in patients allocated ramucirumab plus docetaxel versus placebo plus docetaxel (median 4·07 months [95% CI 2·96-4·47] vs 2·76 months [2·60-2·96]; hazard ratio [HR] 0·757, 95% CI 0·607-0·943; p=0·0118). A blinded independent central analysis was consistent with these results. An objective response was achieved by 53 (24·5%, 95% CI 18·8-30·3) of 216 patients allocated ramucirumab and 31 (14·0%, 9·4-18·6) of 221 assigned placebo. The most frequently reported treatment-emergent adverse events, regardless of causality, in either treatment group (any grade) were fatigue, alopecia, diarrhoea, decreased appetite, and nausea. These events occurred predominantly at grade 1-2 severity. The frequency of grade 3 or worse adverse events was similar for patients allocated ramucirumab and placebo (156 [60%] of 258 vs 163 [62%] of 265 had an adverse event), with no unexpected toxic effects. 63 (24%) of 258 patients allocated ramucirumab and 54 (20%) of 265 assigned placebo had a serious adverse event that was judged by the investigator to be related to treatment. 38 (15%) of 258 patients allocated ramucirumab and 43 (16%) of 265 assigned placebo died on treatment or within 30 days of discontinuation, of which eight (3%) and five (2%) deaths were deemed related to treatment by the investigator. Sepsis was the most common adverse event leading to death on treatment (four [2%] vs none [0%]). One fatal event of neutropenic sepsis was reported in a patient allocated ramucirumab.

INTERPRETATION: To the best of our knowledge, ramucirumab plus docetaxel is the first regimen in a phase 3 study to show superior progression-free survival over chemotherapy in patients with platinum-refractory advanced urothelial carcinoma. These data validate inhibition of VEGFR-2 signalling as a potential new therapeutic treatment option for patients with urothelial carcinoma.

FUNDING: Eli Lilly and Company.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Petrylak DP, de Wit R, Chi KN, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet. 2017. PMID: 28916371. doi:10.1016/S0140-6736(17)32365-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。